Peloton Advantage, a Parsippany-based provider of medical communications services to pharmaceutical, biotechnology and medical device companies, has received an unspecified investment from private equity firm Amulet Capital Partners.
Canadian-based financial services firm BMO Sponsor Finance provided debt financing for the transaction, while investment bank Petsky Prunier acted as exclusive financial advisor to Peloton. Amulet was advised by law firm Latham & Watkins, and Peloton by advised by Gibbons PC.
Peloton specializes in medical affairs, a practice that helps provide a bridge between research and development and the commercialization of a new drug, device or service. The company’s offerings include publication planning and medical writing for drug launches.
The company was founded in 2005 by Michael McLaughlin and Carolyn Clark, who serve as co-presidents. Peoloton has helped clients launch 90 drugs.
Its new funding will be used for growth initiatives.
“In an environment of increasing transparency in scientific communications processes and clinical trial data and the increasing scientific complexity of drugs, the global Medical Affairs market is expected to grow significantly in the next few years,” said Ramsey Frank, partner and co-founder of Amulet, in a written statement.